The safety assessment of genetically modified foods follows internationally harmonized principles established by the Codex Alimentarius, OECD, and national regulatory agencies. The cornerstone of this approach is the concept of substantial equivalence, developed by the OECD in 1993. This comparative approach evaluates whether the GM food is as safe as its conventional counterpart by comparing composition, nutritional characteristics, and potential toxicity and allergenicity. If the GM food is substantially equivalent except for the introduced trait, the safety assessment focuses on the novel protein and any unintended changes.
Compositional analysis is a key component of the safety assessment. The concentrations of key nutrients, anti-nutrients, toxicants, and endogenous allergens in the GM crop are compared to those of a near-isogenic non-GM control grown under identical conditions. The analytes are selected based on the crop species and include proximates, amino acids, fatty acids, vitamins, minerals, and anti-nutrients such as trypsin inhibitors, lectins, and phytic acid. Statistical analysis using a 99-99.7% tolerance interval approach determines whether the GM crop falls within the range of natural variation observed for conventional varieties.
Toxicological assessment includes in silico bioinformatics analysis of the novel protein for homology to known toxins and allergens, in vitro digestibility in simulated gastric fluid (SGF), and acute oral toxicity studies in mice. When indicated by the nature of the introduced trait or compositional differences, 90-day subchronic feeding studies in rodents are conducted according to OECD test guidelines. The WHO and FAO have concluded that approved GM foods on the international market are not toxicologically safer or less safe than their conventional counterparts based on these assessment protocols.
Unintended effects resulting from the genetic modification process are evaluated through targeted compositional analysis and, if concerns arise, through untargeted profiling methods such as metabolomics, proteomics, and transcriptomics. The EFSA Panel on Genetically Modified Organisms provides comprehensive guidance on the information required for GM food and feed risk assessment, including molecular characterization, allergenicity assessment using the weight-of-evidence approach, and post-market environmental monitoring. The FDA’s biotechnology consultation process provides a voluntary but standard regulatory pathway in the United States. Safety assessment is a prerequisite for market approval under labeling and regulation. Substantial equivalence compares GM foods to their conventional counterparts introduced in GM food development. Allergenicity assessment relates to allergen management.
